These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20655910)

  • 21. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice.
    Pardo M; López-Cruz L; Valverde O; Ledent C; Baqi Y; Müller CE; Salamone JD; Correa M
    Behav Brain Res; 2013 Jun; 247():217-26. PubMed ID: 23557694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Stocchi F; Rascol O; Hauser RA; Huyck S; Tzontcheva A; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt DJ;
    Neurology; 2017 Jun; 88(23):2198-2206. PubMed ID: 28490648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.
    Luthra PM; Prakash A; Barodia SK; Kumari R; Mishra CB; Kumar JB
    Neurosci Lett; 2009 Oct; 463(3):215-8. PubMed ID: 19654038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
    Melani A; Cipriani S; Vannucchi MG; Nosi D; Donati C; Bruni P; Giovannini MG; Pedata F
    Brain; 2009 Jun; 132(Pt 6):1480-95. PubMed ID: 19359287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A; Pontis S; Borsini F; Morelli M
    Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
    Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
    Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
    Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM
    Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine A2A antagonists in Parkinson's disease: what's next?
    Hickey P; Stacy M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occupancy of adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T; Iwashita A; Matsuoka N
    Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
    Simola N; Morelli M; Pinna A
    Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A(2A) receptor antagonist.
    Kumari N; Mishra CB; Prakash A; Kumar N; Mongre R; Luthra PM
    Neurosci Lett; 2014 Jan; 558():203-7. PubMed ID: 24161891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.